Esketamine and Spravato
Branded esketamine (Spravato) explained: the S-enantiomer, FDA-approved use in treatment-resistant depression, and how it differs from racemic ketamine.
Branded clinical use
Covers labeling, REMS supervision, and where esketamine fits relative to compounded and IV ketamine.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.
Esketamine for Treatment-Resistant Depression: How It Works
How esketamine (Spravato) treats treatment-resistant depression: FDA approval history, eligibility, dosing schedule, and the REMS safety program.
Esketamine: The S-Enantiomer Behind Spravato
A glossary entry on esketamine, the S-enantiomer of ketamine marketed as Spravato, covering its pharmacology, FDA approval, and clinical significance.
Intranasal Ketamine and Esketamine (Spravato)
Intranasal ketamine and FDA-approved Spravato (esketamine): how dosing works, the REMS clinic visit, side effects, insurance coverage, and what to expect.